Biogen Inc. (BIIB)Healthcare | Drug Manufacturers - General | Cambridge, United States | NasdaqGS
209.03 USD
+9.88
(4.961%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 209.00 -0.03 (-0.030%) ⇩ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:06 a.m. EDT
The most critical signal is the stark contrast between the short-term technical recovery and the long-term capital destruction. While the stock has bounced back to trade above its 50-day and 200-day moving averages, suggesting a short-term bounce, the nine-year cumulative return of minus 46.86 percent reveals a deeper structural issue. The business is showing a divergence where earnings are surging by 31 percent while revenue growth stalls at just 1.9 percent, indicating that the price recovery may be driven by cost-cutting or one-time gains rather than top-line expansion. On the short-term front, the technicals are supportive, but the options market shows a ceiling at 217.50, limiting immediate upside. Long-term, the lack of revenue growth and the massive price decline prevent a confident buy recommendation, leaving the investment case neutral at best. There is no dividend income to offset these risks. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.066084 |
| AutoETS | 0.079576 |
| AutoARIMA | 0.081823 |
| AutoTheta | 0.084588 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 3.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 35.181 |
| Revenue per Share | 67.705 |
| Market Cap | 30,860,587,008 |
| Trailing P/E | 21.42 |
| Forward P/E | 12.55 |
| Beta | 0.16 |
| Profit Margins | 13.80% |
| Website | https://www.biogen.com |
As of July 11, 2026, 5:06 a.m. EDT: Speculators are positioning for a range between 180 and 225, with notable call interest at 225 and 260 suggesting upside hopes, while heavy put open interest at 180 indicates defensive positioning against further downside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.49613106 |
| Address1 | 225 Binney Street |
| All Time High | 480.18 |
| All Time Low | 0.354167 |
| Ask | 221.12 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 1,415,260 |
| Average Daily Volume3 Month | 1,189,524 |
| Average Volume | 1,189,524 |
| Average Volume10Days | 1,415,260 |
| Beta | 0.158 |
| Bid | 197.39 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 126.367 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 209.03 |
| Current Ratio | 3.065 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 210.87 |
| Day Low | 197.74 |
| Debt To Equity | 35.181 |
| Display Name | Biogen |
| Earnings Call Timestamp End | 1,785,355,200 |
| Earnings Call Timestamp Start | 1,785,355,200 |
| Earnings Growth | 0.311 |
| Earnings Quarterly Growth | 0.328 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | 3,539,599,872 |
| Ebitda Margins | 0.35619 |
| Enterprise To Ebitda | 9.363 |
| Enterprise To Revenue | 3.335 |
| Enterprise Value | 33,139,785,728 |
| Eps Current Year | 12.68219 |
| Eps Forward | 16.65804 |
| Eps Trailing Twelve Months | 9.76 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 197.4912 |
| Fifty Day Average Change | 11.538803 |
| Fifty Day Average Change Percent | 0.058426924 |
| Fifty Two Week Change Percent | 49.613106 |
| Fifty Two Week High | 219.72 |
| Fifty Two Week High Change | -10.690002 |
| Fifty Two Week High Change Percent | -0.048652843 |
| Fifty Two Week Low | 121.05 |
| Fifty Two Week Low Change | 87.979996 |
| Fifty Two Week Low Change Percent | 0.72680706 |
| Fifty Two Week Range | 121.05 - 219.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 685,114,200,000 |
| Float Shares | 147,175,013 |
| Forward Eps | 16.65804 |
| Forward P E | 12.548296 |
| Free Cashflow | 1,930,925,056 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 7,500 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.78720003 |
| Gross Profits | 7,822,700,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0018799999 |
| Held Percent Institutions | 0.96291 |
| Implied Shares Outstanding | 147,637,117 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Ir Website | http://www.biogenidec.com/INVESTORS.aspx?ID=5494 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 979,776,000 |
| Last Split Factor | 3:1 |
| Long Business Summary | Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Biogen Inc. |
| Market | us_market |
| Market Cap | 30,860,587,008 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_29726 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 1,371,900,032 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 29,401,931,850 |
| Number Of Analyst Opinions | 31 |
| Open | 199.33 |
| Operating Cashflow | 2,590,799,872 |
| Operating Margins | 0.22899 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.2 |
| Phone | 617 679 2000 |
| Post Market Change | -0.02999878 |
| Post Market Change Percent | -0.014351423 |
| Post Market Price | 209.0 |
| Post Market Time | 1,783,987,089 |
| Previous Close | 199.15 |
| Price Eps Current Year | 16.482168 |
| Price Hint | 2 |
| Price To Book | 1.6541502 |
| Price To Sales Trailing12 Months | 3.1054993 |
| Profit Margins | 0.13805 |
| Quick Ratio | 2.025 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.91667 |
| Region | US |
| Regular Market Change | 9.88 |
| Regular Market Change Percent | 4.96109 |
| Regular Market Day High | 210.87 |
| Regular Market Day Low | 197.74 |
| Regular Market Day Range | 197.74 - 210.87 |
| Regular Market Open | 199.33 |
| Regular Market Previous Close | 199.15 |
| Regular Market Price | 209.03 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,225,896 |
| Return On Assets | 0.059520002 |
| Return On Equity | 0.077010006 |
| Revenue Growth | 0.019 |
| Revenue Per Share | 67.705 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 147,637,117 |
| Shares Percent Shares Out | 0.0388 |
| Shares Short | 5,723,194 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,771,495 |
| Short Name | Biogen Inc. |
| Short Percent Of Float | 0.0432 |
| Short Ratio | 4.96 |
| Source Interval | 15 |
| State | MA |
| Symbol | BIIB |
| Target High Price | 300.0 |
| Target Low Price | 157.0 |
| Target Mean Price | 224.44582 |
| Target Median Price | 222.0 |
| Total Cash | 4,282,700,032 |
| Total Cash Per Share | 29.008 |
| Total Debt | 6,561,900,032 |
| Total Revenue | 9,937,399,808 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 9.76 |
| Trailing P E | 21.417007 |
| Trailing Peg Ratio | 4.1958 |
| Triggerable | 1 |
| Two Hundred Day Average | 179.1149 |
| Two Hundred Day Average Change | 29.9151 |
| Two Hundred Day Average Change Percent | 0.16701625 |
| Type Disp | Equity |
| Volume | 2,225,896 |
| Website | https://www.biogen.com |
| Zip | 2,142 |